FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use
Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:VOPP1-LANCL2

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: VOPP1-LANCL2
FusionPDB ID: 98234
FusionGDB2.0 ID: 98234
HgeneTgene
Gene symbol

VOPP1

LANCL2

Gene ID

81552

55915

Gene nameVOPP1 WW domain binding proteinLanC like 2
SynonymsECOP|GASP|WBP1L2GPR69B|TASP
Cytomap

7p11.2

7p11.2

Type of geneprotein-codingprotein-coding
Descriptionvesicular, overexpressed in cancer, prosurvival protein 1EGFR-coamplified and overexpressed proteinGlioblastoma-amplified secreted proteinVOPP1, WBP1/VOPP1 family memberhypothetical protein DKFZp564K0822putative NF-kappa-B-activating protein 055NlanC-like protein 2G protein-coupled receptor 69BLanC (bacterial lantibiotic synthetase component C)-like 2LanC lantibiotic synthetase component C-like 2testis-specific adriamycin sensitivity protein
Modification date2020031320200313
UniProtAcc.

Q9NS86

Main function of 5'-partner protein: FUNCTION: Necessary for abscisic acid (ABA) binding on the cell membrane and activation of the ABA signaling pathway in granulocytes. {ECO:0000269|PubMed:19667068}.
Ensembl transtripts involved in fusion geneENST idsENST00000285279, ENST00000427700, 
ENST00000418904, ENST00000428097, 
ENST00000428648, ENST00000433959, 
ENST00000453256, ENST00000454227, 
ENST00000471168, ENST00000545390, 
ENST00000486376, ENST00000254770, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score7 X 5 X 5=17512 X 7 X 6=504
# samples 811
** MAII scorelog2(8/175*10)=-1.12928301694497
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(11/504*10)=-2.19592020997526
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: VOPP1 [Title/Abstract] AND LANCL2 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: VOPP1 [Title/Abstract] AND LANCL2 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)LANCL2(55479782)-VOPP1(55565383), # samples:2
VOPP1(55639964)-LANCL2(55459486), # samples:1
Anticipated loss of major functional domain due to fusion event.VOPP1-LANCL2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
VOPP1-LANCL2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
LANCL2-VOPP1 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneLANCL2

GO:0009789

positive regulation of abscisic acid-activated signaling pathway

19667068

TgeneLANCL2

GO:0045892

negative regulation of transcription, DNA-templated

12566319



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:55479782/chr7:55565383)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across VOPP1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across LANCL2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000285279VOPP1chr755639964-ENST00000254770LANCL2chr755459486+38262551081403431

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000285279ENST00000254770VOPP1chr755639964-LANCL2chr755459486+0.0004394430.99956053

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for VOPP1-LANCL2

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
VOPP1chr755639964LANCL2chr75545948625549AKVAALLLGLLLEIIHNFIRRIQTKI

Top

Potential FusionNeoAntigen Information of VOPP1-LANCL2 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
VOPP1-LANCL2_55639964_55459486.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:22LLLGLLLEI0.99370.7474514
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:11LLLGLLLEI0.99290.685514
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:67LLLGLLLEI0.99260.6673514
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:24LLLGLLLEI0.99260.6673514
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:30LLLGLLLEI0.99260.6673514
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:60LLLGLLLEI0.99260.6838514
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:21LLLGLLLEI0.99240.7656514
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:27LLLGLLLEI0.99150.7374514
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:16LLLGLLLEI0.98930.5567514
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:13LLLGLLLEI0.98910.8035514
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:04LLLGLLLEI0.98660.9514
VOPP1-LANCL2chr755639964chr755459486255HLA-B15:01LLLEIIHNF0.9830.683918
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:17LLLGLLLEI0.97710.8445514
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:19LLLGLLLEI0.97360.6459514
VOPP1-LANCL2chr755639964chr755459486255HLA-B15:25LLLEIIHNF0.97260.7406918
VOPP1-LANCL2chr755639964chr755459486255HLA-B15:02LLLEIIHNF0.97010.7545918
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:38LLLGLLLEI0.96860.6023514
VOPP1-LANCL2chr755639964chr755459486255HLA-A32:13LLLEIIHNF0.96710.7499918
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:35LLLGLLLEI0.94030.703514
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:29LLLGLLLEI0.92640.6758514
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:20LLLGLLLEI0.89230.6767514
VOPP1-LANCL2chr755639964chr755459486255HLA-B13:02LLLGLLLEI0.20650.7714514
VOPP1-LANCL2chr755639964chr755459486255HLA-B13:01LLLEIIHNF0.18780.5954918
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:07LLLGLLLEI0.99340.7234514
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:01LLLGLLLEI0.99260.6673514
VOPP1-LANCL2chr755639964chr755459486255HLA-B15:04LLLEIIHNF0.950.6328918
VOPP1-LANCL2chr755639964chr755459486255HLA-B15:05LLLEIIHNF0.83870.56918
VOPP1-LANCL2chr755639964chr755459486255HLA-B15:31LLLEIIHNF0.82880.5691918
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:14LLLGLLLEI0.99250.7718514
VOPP1-LANCL2chr755639964chr755459486255HLA-A02:06LLLGLLLEI0.99240.7656514
VOPP1-LANCL2chr755639964chr755459486255HLA-B15:50LLLEIIHNF0.98610.769918
VOPP1-LANCL2chr755639964chr755459486255HLA-B15:135LLLEIIHNF0.98460.6757918
VOPP1-LANCL2chr755639964chr755459486255HLA-B15:27LLLEIIHNF0.98430.6932918
VOPP1-LANCL2chr755639964chr755459486255HLA-B15:34LLLEIIHNF0.9830.683918
VOPP1-LANCL2chr755639964chr755459486255HLA-B15:125LLLEIIHNF0.9830.683918
VOPP1-LANCL2chr755639964chr755459486255HLA-B15:33LLLEIIHNF0.9830.683918
VOPP1-LANCL2chr755639964chr755459486255HLA-B15:24LLLEIIHNF0.980.6671918
VOPP1-LANCL2chr755639964chr755459486255HLA-A32:01LLLEIIHNF0.97930.7706918
VOPP1-LANCL2chr755639964chr755459486255HLA-B15:12LLLEIIHNF0.97140.6886918
VOPP1-LANCL2chr755639964chr755459486255HLA-B15:35LLLEIIHNF0.97130.5534918
VOPP1-LANCL2chr755639964chr755459486255HLA-B15:20LLLEIIHNF0.86010.718918
VOPP1-LANCL2chr755639964chr755459486255HLA-B35:28LLLEIIHNF0.81960.7036918
VOPP1-LANCL2chr755639964chr755459486255HLA-B35:20LLLEIIHNF0.80070.7128918

Top

Potential FusionNeoAntigen Information of VOPP1-LANCL2 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
VOPP1-LANCL2_55639964_55459486.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
VOPP1-LANCL2chr755639964chr755459486255DRB1-1102LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1102LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1103LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1116LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1116LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1121LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1121LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1148LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1148LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1163LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1165LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1165LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1170LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1170LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1176LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1185LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1301LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1301LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1308LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1308LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1309LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1315LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1315LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1317LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1317LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1319LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1322LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1322LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1324LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1335LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1335LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1351LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1351LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1352LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1352LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1353LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1357LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1357LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1359LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1359LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1364LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1364LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1368LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1368LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1369LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1369LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1370LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1370LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1372LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1372LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1379LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1379LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1380LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1380LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1383LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1383LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1384LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1384LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1387LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1387LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1391LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1391LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1392LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1392LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB1-1398LLEIIHNFIRRIQTK1025
VOPP1-LANCL2chr755639964chr755459486255DRB1-1398LEIIHNFIRRIQTKI1126
VOPP1-LANCL2chr755639964chr755459486255DRB5-0202GLLLEIIHNFIRRIQ823
VOPP1-LANCL2chr755639964chr755459486255DRB5-0205GLLLEIIHNFIRRIQ823
VOPP1-LANCL2chr755639964chr755459486255DRB5-0205LGLLLEIIHNFIRRI722

Top

Fusion breakpoint peptide structures of VOPP1-LANCL2

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
5219LLGLLLEIIHNFIRVOPP1LANCL2chr755639964chr755459486255

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of VOPP1-LANCL2

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN5219LLGLLLEIIHNFIR-7.61104-7.72884
HLA-B14:023BVN5219LLGLLLEIIHNFIR-5.32714-6.37614
HLA-B52:013W395219LLGLLLEIIHNFIR-7.6944-7.8122
HLA-B52:013W395219LLGLLLEIIHNFIR-5.60826-6.65726
HLA-A11:014UQ25219LLGLLLEIIHNFIR-10.9678-11.0856
HLA-A11:014UQ25219LLGLLLEIIHNFIR-3.20482-4.25382
HLA-A24:025HGA5219LLGLLLEIIHNFIR-6.35658-7.40558
HLA-A24:025HGA5219LLGLLLEIIHNFIR-5.81901-5.93681
HLA-B44:053DX85219LLGLLLEIIHNFIR-7.24859-8.29759
HLA-B44:053DX85219LLGLLLEIIHNFIR-7.24668-7.36448

Top

Vaccine Design for the FusionNeoAntigens of VOPP1-LANCL2

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
VOPP1-LANCL2chr755639964chr755459486514LLLGLLLEICTGCTGCTCGGGCTGCTCTTGGAGATC
VOPP1-LANCL2chr755639964chr755459486918LLLEIIHNFCTGCTCTTGGAGATCATTCATAATTTC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
VOPP1-LANCL2chr755639964chr7554594861025LLEIIHNFIRRIQTKCTCTTGGAGATCATTCATAATTTCATAAGACGGATCCAGACCAAA
VOPP1-LANCL2chr755639964chr7554594861126LEIIHNFIRRIQTKITTGGAGATCATTCATAATTTCATAAGACGGATCCAGACCAAAATT
VOPP1-LANCL2chr755639964chr755459486722LGLLLEIIHNFIRRICTCGGGCTGCTCTTGGAGATCATTCATAATTTCATAAGACGGATC
VOPP1-LANCL2chr755639964chr755459486823GLLLEIIHNFIRRIQGGGCTGCTCTTGGAGATCATTCATAATTTCATAAGACGGATCCAG

Top

Information of the samples that have these potential fusion neoantigens of VOPP1-LANCL2

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
GBMVOPP1-LANCL2chr755639964ENST00000285279chr755459486ENST00000254770TCGA-06-A6S0-01A

Top

Potential target of CAR-T therapy development for VOPP1-LANCL2

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to VOPP1-LANCL2

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to VOPP1-LANCL2

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource